BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019;8:41-65. [PMID: 30815394 DOI: 10.1159/000490360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
2 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cao Z, Cheng Y, Wang J, Liu Y, Yang R, Jiang W, Li H, Zhang X. HBP1-mediated transcriptional repression of AFP inhibits hepatoma progression. J Exp Clin Cancer Res 2021;40:118. [PMID: 33794968 DOI: 10.1186/s13046-021-01881-2] [Reference Citation Analysis]
4 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. J Hepatol 2019;71:889-99. [PMID: 31295532 DOI: 10.1016/j.jhep.2019.06.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
6 Zhang P, He B, Cai Q, Tu G, Peng X, Zhao Z, Peng W, Yu F, Wang M, Tao Y, Wang X. Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity. Front Oncol 2021;11:705888. [PMID: 34568032 DOI: 10.3389/fonc.2021.705888] [Reference Citation Analysis]
7 Karbeyaz F, Kissling S, Jaklin PJ, Bachofner J, Brunner B, Müllhaupt B, Winder T, Mertens JC, Misselwitz B, von Felten S, Siebenhüner AR. Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. J Hepatocell Carcinoma 2021;8:565-74. [PMID: 34150679 DOI: 10.2147/JHC.S289955] [Reference Citation Analysis]
8 Rinaldi L, Nevola R, Franci G, Perrella A, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel) 2020;12:E1351. [PMID: 32466400 DOI: 10.3390/cancers12061351] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
9 Fang Z, Guo Y, Wang Z, He T, Wang J, Bai Z, Xiao X. Asari radix et rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: A retrospective cohort study. Chinese Herbal Medicines 2022. [DOI: 10.1016/j.chmed.2022.01.004] [Reference Citation Analysis]
10 Zhao Q, Wongpoomchai R, Chariyakornkul A, Xiao Z, Pilapong C. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. Front Oncol 2021;11:740484. [PMID: 34745960 DOI: 10.3389/fonc.2021.740484] [Reference Citation Analysis]
11 Chen W, Zhang X, Bi K, Zhou H, Xu J, Dai Y, Diao H. Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. Front Oncol 2020;10:554165. [PMID: 33072579 DOI: 10.3389/fonc.2020.554165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Wang G, Wan H, Jian X, Li Y, Ouyang J, Tan X, Zhao Y, Lin Y, Xie L. INeo-Epp: A Novel T-Cell HLA Class-I Immunogenicity or Neoantigenic Epitope Prediction Method Based on Sequence-Related Amino Acid Features. Biomed Res Int 2020;2020:5798356. [PMID: 32626747 DOI: 10.1155/2020/5798356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 2020;11:571166. [PMID: 33133084 DOI: 10.3389/fimmu.2020.571166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Merritt E, Londoño MC, Childs K, Whitehouse G, Kodela E, Sánchez-Fueyo A, Martínez-Llordella M. On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation. Am J Transplant 2021;21:247-57. [PMID: 32524678 DOI: 10.1111/ajt.16134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Ebel F, Deterding K, Port K, Schlevogt B, Manns MP, Maasoumy B, Cornberg M, Wedemeyer H. Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. Aliment Pharmacol Ther 2020;51:194-5. [PMID: 31850589 DOI: 10.1111/apt.15597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Owusu Sekyere S, Port K, Deterding K, Cornberg M, Wedemeyer H. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. United European Gastroenterol J 2021;9:486-96. [PMID: 33349201 DOI: 10.1177/2050640620976991] [Reference Citation Analysis]